Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $35.9900 (9.36%) ($32.9100 - $36.2500) on Mon. Mar. 2, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.77% (three month average) | RSI | 88 | Latest Price | $35.9900(9.36%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA advances 7.3% a day on average for past five trading days. | Weekly Trend | IOVA advances 21.2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) IBB(49%) ARKG(48%) XBI(48%) IWO(44%) ARKK(43%) | Factors Impacting IOVA price | IOVA will decline at least -2.385% in a week (0% probabilities). VIXM(-28%) VXX(-16%) UUP(-10%) TLT(-2%) TBT(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.385% (StdDev 4.77%) | Hourly BBV | 0 () | Intraday Trend | 8.8% | | | |
|
5 Day Moving Average | $33.41(7.72%) | 10 Day Moving Average | $29.41(22.37%) | 20 Day Moving Average | $26.51(35.76%) | To recent high | 0% | To recent low | 66.3% | Market Cap | $5.27b | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |